{"nctId":"NCT00046228","briefTitle":"A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)","startDateStruct":{"date":"2002-08"},"conditions":["Myocardial Infarction"],"count":2461,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: abciximab placebo; reteplase placebo, abciximab, abciximab","Drug: Abciximab; reteplase; abciximab placebo; abciximab"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: Abciximab; reteplase; abciximab placebo; abciximab","Drug: abciximab; reteplase placebo; abciximab placebo; abciximab"]},{"label":"003","type":"EXPERIMENTAL","interventionNames":["Drug: abciximab; reteplase placebo; abciximab placebo; abciximab","Drug: abciximab placebo; reteplase placebo, abciximab, abciximab"]}],"interventions":[{"name":"abciximab placebo; reteplase placebo, abciximab, abciximab","otherNames":[]},{"name":"Abciximab; reteplase; abciximab placebo; abciximab","otherNames":[]},{"name":"abciximab; reteplase placebo; abciximab placebo; abciximab","otherNames":[]},{"name":"abciximab placebo; reteplase placebo, abciximab, abciximab","otherNames":[]},{"name":"abciximab; reteplase placebo; abciximab placebo; abciximab","otherNames":[]},{"name":"Abciximab; reteplase; abciximab placebo; abciximab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have prolonged, continuous (lasting at least 20 minutes) signs and symptoms of A heart attack not eliminated with nitrates and onset within 6 hours of randomization,and confirmation by Electrocardiogram\n\nExclusion Criteria:\n\n* Low risk clinical presentation\n* patients who will not be undergoing a catherization within 4 hours of the qualifying Electrocardiogram","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Composite of All-Cause Mortality or Complications of MI at 90 Days.","description":"Occurs within 90 days and is composite of all-cause mortality or complications of myocardial infarction (MI) (rehospitalization or emergency department visit for congestive heart failure (CHF), cardiogenic shock, or resuscitated ventricular fibrillation occurring \\> 48 hours after randomization).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Complications of MI as Defined in the Primary Outcome Measure Through 90 Days","description":"The complications of myocardial infarction (MI) is defined as any event of rehospitalization or emergency department visit for CHF, cardiogenic shock, or resuscitated ventricular fibrillation occurring \\> 48 hours after randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"All-Cause Mortality Through 90 Days","description":"All cause mortality occurred through 90 days from randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects With ST-Segment Resolution > 70% From Baseline at 60 to 90 Minutes Following Randomization","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]}]},{"type":"SECONDARY","title":"All-Cause Mortality Through 1 Year","description":"All-cause mortality through 1 year from randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Subjects With Intracranial Hemorrhage (Including Hemorrhagic Transformation) Through Discharge/Day 7","description":"All cases of cerebrovascular event were confirmed by a CEC (Clinical Endpoints Committee).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Subjects With Non Intracranial Thrombolysis In Myocardial Infarction (TIMI) Bleeding Events Through Discharge/Day 7","description":"Subjects with nonintracranial TIMI bleeding (either major or minor) through discharge/day 7, originating from vascular instrumentation sites, non-instrument related bleeding, as well as overall, were examined.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"118","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Subjects With Severe Thrombocytopenia Through Discharge/Day 7","description":"Severe thrombocytopenia is defined as platelet count \\< 50,000 cells/Î¼L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Subjects With Any Investigator Reported Bleeding Events Through Discharge/Day 7","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"178","spread":null},{"groupId":"OG002","value":"271","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Subjects With Pre-Specified Complications of Index Myocardial Infarction Through Discharge/Day 7","description":"Number of subjects with one or more of the following: 2nd or 3rd Degree AVB, Asystole, Sustained V Tach, A Fib/Flutter, EMD/Pulseless Electrical Activity, Heart Failure, Tamponade, Myocardial Rupture, Papillary Muscle Rupture, Ventricular Septal Defect, Pulmonary Embolism, Systemic Arterial Embolism and/or Pericarditis/Pericardial Effusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"122","spread":null},{"groupId":"OG002","value":"120","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":159,"n":795},"commonTop":[]}}}